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Summary Monoclonal antibodies reactive with placental-type alkaline phosphatase have formed the basis of
methods for detection of this oncodevelopmental antigen in patients with pre-invasive and invasive cervical
neoplasia, with or without evidence of papilloma virus infection. Disease-related elevations of placental-type
alkaline phosphatase were not observed in patients' sera. Solubilised cervical smears or biopsy material, and
cervical mucus swabs, often contained substantial amounts of this isoenzyme; however, there was no
significant difference between any of the patient and control groups. Thus, serological and smear test assays
for placental-type alkaline phosphatase were not useful in differential diagnosis of cervical lesions. However,
its presence in most biopsy specimens, often at high levels, indicated possible application for in vivo
radioimmunoimaging studies of invasive or metastatic cervical cancer.
The incidence of cervical cancer has increased markedly in
younger women over the last two decades, in part due to
venereal transmission of papilloma virus (HPV) infection
(Crawford, 1984). It is not clear whether HPV infection can
be a forerunner of cervical intraepithelial neoplasia (CIN),
but progression of CIN into overt cancer may be related to
concomitant infection by HPV (Syrjanen et al., 1985).
Screening for pre-invasive cervical carcinoma involves
exhaustive examination of smears, and therefore simple rapid
techniques for identifying pre-invasive cervical neoplasia are
attractive to seek.
Potential markers for neoplastic cellular transformation
are the oncodevelopmental antigens, such as placental-type
alkaline phosphatase. This isoenzyme is a major glycoprotein
of term placental trophoblast membranes, and is also
expressed on some tumour cell lines including cervical
carcinoma cells (McLaughlin et al., 1982). Two major forms
of placental-type alkaline phosphatase have been described,
the 'placental' and 'placental-like' alkaline phosphatases
(PLAP and PLAP-like AP, respectively). These can be
distinguished by relative sensitivity to inhibition by L-leucine
(Stigbrand et al., 1982) and differential reactivity with certain
monoclonal antibodies (mAbs) (McLaughlin & Johnson,
1984).
The development of sensitive and specific solid-phase
enzyme capture immunoassays (EIA) utilising either the
mAb H317 (reactive solely with PLAP) or the mAb H17-E2
(reactive with both PLAP and PLAP-like AP) has broadened
investigations of this isoenzyme group in cancer
(McLaughlin et al., 1983; 1984a, b; Epenetos et al., 1985a;
Horwich et al., 1985; Tucker et al., 1985). For example,
previous serological assays have been limited by detection of
elevated isoenzyme levels in healthy individuals, particularly
cigarette smokers (Maslow et al., 1983; Tonik et al., 1983). It
is now clear that this smoking-associated enzyme is PLAP-
like AP, rather than PLAP, and thus ig unreactive in the
H317-based assay (McLaughlin et al., 1984b). Both H317
and H17-E2 have now been used to evaluate PLAP and
PLAP-like AP in pre-invasive and established cervical
neoplasia. Four approaches were developed: EIA assay of
PLAP and PLAP-like AP in serum, solubilised cervical
biopsy tissue material, cervical smears and cervical mucus
swabs.
Patients and methods
Patients
The study groups for CIN were taken from a total of 48
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women attending a colposcopy clinic at the Royal Liverpool
Hospital, and 68 outpatients seen at the Royal Northern
Hospital, London, because of abnormal cytology. Cervical
punch biopsies were classified as normal, CIN I, CIN IT or
CIN III. These were further subdivided into those having
evidence of HPV infection of the cervix (46%) and those
appearing virus-free (54%), as assessed by macroscopic
appearance of the cervix and light microscopic examination
of smear and biopsy samples. Features suggestive of HPV
infection, based on histological appearance, were the
presence of keratinisation, papillomatosis, perinuclear vacu-
olation and observation of eosinophilic bodies within cells.
Twelve patients from the Oxford region with established
cancer of the cervix were also studied. These had squamous
carcinoma (n=9), adenocarcinoma (n=2) or mixed
squamous and adenocarcinoma (n= 1); three of the
carcinomas were Stage IA, five were Stage IB, three were
IIA, and one was IIB.
Monoclonal antibodies (mAbs)
The H317 and H17-E2 hybridomas had been produced
following immunisation of mice with isolated human term
placental syncytiotrophoblast microvilli (McLaughlin et al.,
1982, Travers & Bodmer, 1984). The secreted mAbs are both
IgGI and were purified from ascitic fluid by affinity chroma-
tography with Sepharose-protein-A (Pharmacia) (Ey et al.,
1978). The H17-E2 mAb reacts with both PLAP and PLAP-
like AP, whereas the H317 mAb reacts only with PLAP;
neither mAb reacts with non-placental-type alkaline phos-
phatase isoenzymes (McLaughlin et al., 1982, 1983; Travers
& Bodmer, 1984).
Enzyme immunoassays (EIA)
A solid-phase capture assay for PLAP in body fluids, based
on the, H317 mAb, has been described in detail (McLaughlin
et al., 1983; 1984b). The lower limit of detection is less than
0.1U -1, and none of 120 healthy individuals had serum
PLAP levels of >0.1U -1. The H17-E2 mAb has formed
the basis of a similar EIA which measures both PLAP and
PLAP-like AP (Tucker et al., 1985). The lower limit of
detection is 0.04U P1 , but occasional healthy individuals
and most cigarette smokers have serum levels substantially
greater than this (Tucker et al., 1985) and which appears to
be PLAP-like AP rather than PLAP (McLaughlin et al.,
1984b).
Solubilised tissue extracts
Cervical biopsy samples (2-15mg wet weight tissue) were
suspended in 50vol of PBS with 0.05% Tween 20, pH7.4,
and sonicated for a total of 2min at 4°C. Residual fine
particles were allowed to settle for 30min and the super-
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natants assayed for placental-type alkaline phosphatases by
EIA with a lower limit of detection of 5Ukg-1 tissue.
Cervical smear assay
Spatula smear material was solubilised with 2ml 0.2%
sodium deoxycholate in 0.1 M phosphate buffer, pH 8.5. The
suspension was centrifuged at 900g for 15min and the
supernatant assayed for both protein (Lowry et al., 1951)
and placental-type alkaline phosphatases by EIA with a
lower limit of detection of 0.5Ug 1 protein.
Cervical swab assay
A swab of endocervical mucus was placed in 3ml PBS,
pH7.4, and agitated to disperse the mucus. This material
was then assayed for placental-type alkaline phosphatases by
EIA. Results were expressed as U 1-I.
Cervical mucus samples from normal subjects were
collected at a family planning clinic in Sheffield by Dr Nigel
Saunders, Department of Obstetrics & Gynaecology,
Northern General Hospital, Sheffield.
Results
Serological assay
Circulating H317-reactive PLAP (>0.1 U 11) was not
detected in any of 22 CIN patients or 12 patients with
established cervical cancer, with or without evidence of HPV
infection. However, 12 of these sera did contain H17-E2-
reactive PLAP-like AP; this correlated with the expected
pattern for smoking-associated circulating PLAP-like AP,
since 11 of these 12 patients were cigarette smokers.
Cervical tissue biopsies
Of biopsies taken, 31/35 (89%) had detectable placental-type
alkaline phosphatase activity in solubilised tissue extracts
which was reactive with both H317 and H17-E2 (Figure 1).
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The Hi7-E2 reactivity was greater than H317 reactivity in
most cases, reflecting co-expression of both PLAP and
PLAP-like AP. There was no correlation between placental-
type alkaline phosphatase levels and degree of dysplasia or
presence of HPV infection of the cervix.
Cervical smears
Solubilised smears contained placental-type alkaline phos-
phatase activity detectable using both H317 and H17-E2 in
14/29 (48%) cases studied (Figure 2). There was reactivity
with H17-E2 but not H317 in a further 7 cases (24%), and
smears from 8 cases (28%) contained no detectable
placental-type alkaline phosphatase reactivity by either assay.
There was no difference in distribution of isoenzyme
activities between any of the patient groups.
Both biopsy material and smears were available from 16
patients. Patients with high tissue biopsy placental-type
alkaline phosphatase activities often also had high iso-
enzymic activity in solubilised smears, although this was not
statistically significant by product-moment correlation
coefficient analysis.
Cervical swabs
There was a wide range for placental-type alkaline
phosphatase activity in swab material (Figure 3) similar to
that for the smear assay. Over half the samples (51/93, 55%)
were reactive in both the H317-based and H17-E2-based
assays, and only 29/93 (31%) were negative in both assays.
Six of 12 (50%) patients with established cervical cancer had
placental-type alkaline phosphatase in cervical mucus detect-
able with both H317 and H17-E2. This was a similar
proportion to that found in CIN patients or normal (no
CIN) controls (Figure 3).
The nature of the mucus and its rate of production change
around the time of ovulation (Bloom & Fawcett, 1975),
although cervical swab placental-type alkaline phosphatase
levels compared at different stages of the menstrual cycle,
showed no significant differences.
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Figure 1 Placental-type alkaline phosphatase activity in cervical biopsy material. 0: H17-E2-reactive activity; *: H317-reactive
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Figure 2 Placental-type alkaline phosphatase activity in cervical smear material. 0: H17-E2-reactive activity; 0: H317-reactive
activity; HPV: evidence of HPV infection.
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Figure 3 Placental-type alkaline phosphatase activity in cervical mucus. 0: H17-E2-reactive activity; 0: H317-reactive activity;
HPV: evidence of HPV infection.
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Discussion
Although circulating H317-reactive PLAP was not detected
in this study in pre-invasive or established cervical neoplasia,
serum H17-E2-reactive PLAP-like AP was detected in many
patients from both groups which correlated better with
smoking habits than with cervical disease status. It is of
interest that cigarette smoking can lead to an increased risk
of cervical cancer (Greenberg et al., 1985), possibly resulting
from local excretion of absorbed carcinogenic products of
cigarette smoke (Winkelstein et al., 1984). However, the
original source of the serum PLAP-like AP in these patients
is thought most likely to be local release from lung alveolar
tissue (Williams et al., 1986).
Cervical biopsy tissue contained both PLAP and PLAP-
like AP, as reflected by generally higher isoenzymic activity
detected using H17-E2 (reactive with PLAP and PLAP-like
AP) than with H317 (reactive with PLAP alone). The levels
of activity fell within a wide range, as previously noted for
normal cervical tissue (Goldstein et al., 1980; McLaughlin et
al., 1984a), but did not reflect the degree of cellular dysplasia
or other cervical pathology. Despite high levels of biopsy
PLAP activity in some patients, the isoenzyme was not
significantly released intact into the peripheral circulation.
Previous studies have also shown that tumour tissue levels of
placental-type alkaline phosphatase do not necessarily
correlate with circulating levels in ovarian or breast
carcinoma (McDicken et al., 1983, 1985). However, secretion
of this isoenzyme into cervical mucus was more evident.
Although high levels were often found, these did not
correlate with cervical disease status. The precise cellular
source of this activity has not been defined but endo-
metrium, endocervical and fallopian tube epithelia are all
known to express placental-type alkaline phosphatase
(Davies et al., 1985). We have attempted immunocytology on
cervical smears using both H317 and H17-E2 in an indirect
immunoperoxidase staining technique; however, no clear
differences were noted between normal or abnormal cervix.
The high levels of cervical tissue PLAP and PLAP-like AP
activities suggest a potential as targets for radioimmuno-
localisation of invasive and metastatic disease, as has been
performed successfully in ovarian and testicular cancer
(Epenetos et al., 1985b; Critchley et al., 1986), or for
determining the extent of lymphatic spread by lymphangio-
graphy as has been attempted in cervical cancer using the
HMFG2 mAb (Epenetos, 1985).
There was no significant difference for either PLAP or
PLAP-like AP levels between smear, swab or biopsy
specimens from HPV-infected compared with HPV-free
material. Of 81 patients with CIN, 46% had been designated
as having HPV infection of the cervix. This figure, however,
is low compared with 70-90% found by McCance et al.
(1985) using the more sensitive techniques of DNA
hybridisation.
In conclusion, neither circulating nor cervical smear PLAP
or PLAP-like AP was found to be a useful parameter of
disease status in patients with pre-invasive or established
neoplastic lesions of the cervix. Nevertheless, the presence of
high levels of PLAP and PLAP-like AP activities within
many of these tissues suggests the possibility of effective
radioimmunolocalisation of invasive and metastatic disease.
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